Cellino Biotech, Inc., a preclinical biotechnology company building an autonomous biomanufacturing platform for personalized regenerative medicine, today announced the expansion of its executive leadership team with the addition of Ed Tekeian as Senior Vice President of Engineering. As an experienced engineering leader who has spearheaded the development of products ranging from SaaS applications for 3D […]

We’re getting closer to this year’s Early Stage meet-up in Boston. Tobi Coker from Felicis, Julia Neagu from Quotient AI, and Nabiha Saklayen from Cellino will be there to answer your most pressing questions.

As the number of regenerative medicines and therapies approved by the Food and Drug Administration (FDA) has grown to meet rising demand, the field of regenerative medicine has started to anticipate the potential of strategies such as artificial intelligence, decentralized manufacturing, and automation to accommodate this expansion. The National Academies Forum on Regenerative Medicine hosted […]

To hear venture capitalist Alex Morgan tell it, investors shouldn’t be in the business of predicting trends. “There’s often a public perception that we’re in the prediction game,” said Morgan, a partner at Khosla Ventures who oversees the firm’s biotechnology investments. “We’re not trying to be. As an early-stage venture investor, we’re trying to imagine […]

Last week marked the historic Food and Drug Administration approval of the first CRISPR therapy. Five other Nobel-winning breakthroughs have led to recent new medicines.

The Cell & Gene Meeting on the Mesa 2023 featured a Science Slam on Autologous iPSC-Derived Cell Therapies. This session, moderated by Marinna Madrid, Ph.D., Co-Founder & Chief Product Officer at Cellino, provided an overview of recent progress in the field and addressed potential challenges for this critical therapeutic modality.

The inaugural Personalized RegenMed Forum, hosted by Cellino in Cambridge, MA, was the first in-person gathering for personalized regenerative medicine therapy developers, champions, and thought leaders. The Forum celebrated the progress of personalized regenerative medicines and the emerging industry surrounding them.

Cell and gene therapies were set to take the market by storm and transform the treatment landscape. But more than five years out from the first approval in 2017, fewer cell and gene therapies have been approved in the US than expected. The cost of developing and manufacturing these transformative therapies remains astronomical and has […]

The Forum on Regenerative Medicine hosted a public workshop focusing on the challenges and opportunities in manufacturing regenerative medicine therapeutics. During this event, Nabiha Saklayen, CEO & Co-Founder of Cellino, contributed to “SESSION III: Automation and Algorithms in Regenerative Medicine Manufacturing,” alongside moderator Sohel Talib from the California Institute for Regenerative Medicine (CIRM).

Nabiha Saklayen founded Cellino Biotech just as she was finishing her PhD in physics at Harvard in 2017, while she was still in her 20s. The startup is trying to create automated ways to produce cell therapies and raised an $80 million Series A round in 2022 to get to work. Endpoints News caught up with Saklayen […]

Aufbruchstimmung in der Biotechforschung. Mit Künstlicher Intelligenz wollen Wissenschaftler Krankheiten wie Krebs besiegen. Doch mit der neuen Technik steigen auch die Gefahren. Boston, New York Die „Bio International Convention“ ist eine der wichtigen Fachmessen der Biotechbranche. 19.000 Ärzte, Wissenschaftler und Analysten kamen Anfang Juni in Boston zusammen, um über das Neueste vom Neuen zu sprechen.

Cellino Biotech, Inc., the cell therapy biomanufacturing company unlocking personalized regenerative medicine at scale, has been named the winner of the “Scalable Solutions” category of the Advanced Research Projects Agency for Health’s (“ARPA-H”) inaugural Dash to Accelerate Health Outcomes. Cellino was also named overall first runner-up out of 64 teams after six rounds of voting.

Cellino Biotech, Inc., an autologous cell therapy technology platform company, today announced that Chief Operating Officer Abhijit Kulkarni, Ph.D., was inducted to The American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.

While several Leaps companies are working on diverse therapeutic approaches, Cellino aims to dramatically expand access to cell therapies, leveraging high-speed laser editing with machine learning to automate cell therapy manufacturing.

Advances in scientific research suggest the possibility of a viable biosynthetic blood technology that could radically transform the health outcomes of people around the world. Such a development would enhance a drastically insufficient global supply of red blood cells needed for transfusions, while also mitigating severe risks to donor supply precipitated by future pandemic or […]

Nabiha Saklayen hopes to transform medicine with lasers and stem cells.

Cellino is on a mission to democratize access to personalized stem-cell-based therapies. These types of therapies, which involve transplanting healthy stem cells into a patient’s body, can be used to treat diseases, including Parkinson’s, cancer, and heart disease. The issue is that it’s hard to manufacture enough of these cells on a large scale.

Bayer recently welcomed its partners and media to its new Bayer Research and Innovation Center (BRIC) in Cambridge, MA. The state-of-the-art innovation facility is home to the company’s precision molecular oncology laboratory and reflects the investment Bayer is making to advance the future of oncology and science and generate breakthrough solutions to the world’s most […]

Cellino Biotech, Inc., an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer. Together, these leaders will support the company’s growth and further enhance its […]

Meet #Cellino, a Leaps portfolio company that aims to make personalized #celltherapies available at scale through advanced manufacturing. Founder and CEO Nabiha Saklayen shares her insight into the potential of cell therapies to change the course or even cure some of the most challenging diseases. Cellino’s unique interdisciplinary approach aims to automate the manufacturing process, […]

The rapid advances in cell therapy are among the most exciting avenues for the future of biotech. As I have written before, an emerging field of cell therapies harnesses the incredible powers of induced pluripotent stem cells (iPSCs) to regenerate tissues lost and damaged in conditions like Parkinson’s disease, heart disease, retinal disease, diabetes and […]

A year ago, Cellino announced its seed round and came out of stealth mode with a bold vision: “Every human. Every Cell,” crystallizing the company’s purpose and a startup was brought to life. The team is pioneering outstanding science and technology that will make a large impact, not just for the biotech industry, but change […]

Via $80M A round for manufacturing play, Bayer deepens its reach into next-gen cell therapy technologies

Today is a special day, in more ways than one. I, along with the rest of the Felicis team, am celebrating the announcement of an investment into a company we are extremely excited about, Cellino.

The summer before Cellino CEO and co-founder Nabiha Saklayen started at Harvard, she lost her grandmother following complications to diabetes. Before then, she hadn’t taken a biology class since ninth or tenth grade — the mark of a classic physicist — but it was then she decided she wanted the rest to sit at the […]

Today, Cellino Biotech, an autonomous cell therapy manufacturing company, announced an $80 million Series A financing round led by Leaps by Bayer along with 8VC, Humboldt Fund, and new investors including Felicis Ventures and Khosla Ventures, that could fix a problem holding the biotech industry back. Cellino plans to expand access to stem cell-based therapies with […]

Since it was established in 2017, Cellino Biotech has offered an intriguing approach to stem cell therapy manufacturing, combining biology, laser physics, gene editing tools and machine learning.  In April of last year, the Cambridge, Massachusetts, startup attracted $16 million in financing. Now, nine months later, it has a major player into its corner.  Bayer […]

Cellino Bio’s founder Nabiha Saklayen didn’t initially intend to enter TechCrunch Disrupt 2021’s Startup Battlefield – it was her PR advisor who threw the startup’s name in the ring as a wildcard entry. But after a busy weekend for the team, Cellino walked away with the prize anyway. Just a few months later, Cellino has […]

Cellino aims to significantly expand patient access to stem cell-based therapies with autonomous end-to-end manufacturing Proceeds will expand machine learning, software, and hardware capabilities and to develop early-stage Good Manufacturing Practice (GMP) capabilities to support clinical trials, with plans to build the first autonomous human cell foundry in 2025 Investment further strengthens existing company portfolio […]

Growing up with a love of astrology, Cellino Biotech founder now advances stem cell treatments.

What if diseases could be treated with a patient’s own cells, precisely and on demand? Biotech entrepreneur Nabiha Saklayen explains how we could harness advances in biology, machine learning and lasers to create personalized stem cell banks — and develop medicine uniquely designed for each of our bodies.

We started this competition with 20 impressive startups. After three days of fierce pitching in the virtual yet incredibly competitive Startup Battlefield arena, we have a winner: Cellino.

Cellino, a company developing a platform to automate stem cell production, presented today at TechCrunch Disrupt 2021 to detail how its system, which combines A.I. technology, machine learning, hardware, software — and yes, lasers! — could eventually democratize access to cell therapies. It aims to bring down costs associated with the manufacturing of human cells, […]

Cellino, a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.

Are autologous iPSC-derived cell therapies ready to hit prime time? A conversation between Alex Morgan, Partner at Khosla Ventures, and a panel of distinguished experts in autologous iPSC cell therapies will address the breakthroughs in the space. What new advancements in autologous cell therapies are already available to make sure patients can best benefit given […]

Nabiha Saklayen is co-founder and chief executive of US start-up Cellino Biotech, which uses biophysics technologies to advance personalized regenerative medicine. She talks to Julianna Photopoulos about the importance of multidisciplinarity for tackling real-world problems.

Cellino, a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced that its CEO Dr. Nabiha Saklayen has been awarded the first Tory Burch Fellowship at the International Genomics Institute (IGI).

Fast Company announces new partnership with Tory Burch Foundation and Jennifer Doudna and the Innovative Genomics Institute, featuring their inaugural one-year fellowship program to support entrepreneur and scientist Nabiha Saklayen, PhD, Co-Founder & CEO of Cellino, a company working on personalized cell therapies.

Cellino Biotech CEO and Co-founder Dr. Nabiha Saklayen talked about the formation of the company and its goal to make stem cell therapies accessible for patients.

The promise of human induced pluripotent stem cells (iPSCs) lies in their ability to serve as a starting material for autologous, or patient‐specific, stem cell–based therapies. Since the first publications describing the generation of iPSCs from human tissue in 2007, a Phase I/IIa clinical trial testing an autologous iPSC‐derived cell therapy has been initiated in […]

During the holidays, Alex Morgan, Partner at Khosla Ventures, sat down with Nabiha Saklayen, CEO and co-founder of Cellino, to learn more about her and the company.  Cellino has a unique technique technology for AI-guided laser editing of stem cells for personalized therapies. The company’s goal is to make autologous stem cell manufacturing scalable for the first time.  […]

CEO Nabiha Saklayen founded Cellino in 2017 while still in her mid-20s (she’s since gone on to be named to Forbes’ 30 Under 30 list and MIT Tech Review’s 35 Innovators Under 35 list), and told Endpoints News in a statement that the technology has the potential to eliminate “a major bottleneck” in the stem cell […]

Cambridge, Mass.-based Cellino has raised $16 million in venture capital to scale up a technology that could be vital as stem-cell research expands. Its system is designed to automate the now labor-intensive process of generating induced-pluripotent stem cells that are derived from patients’ own cells.

Top-tier investor syndicate co-led by The Engine and Khosla Ventures, with participation from Humboldt Fund and 8VC. The financing will be used to advance its AI-guided laser platform to automate and scale autologous cell-and tissue-based therapies.

A Forbes 30 Under 30 alum from 2019, Cellino Biotech is making waves— and tissues. The Cambridge, Massachusetts-based company, backed by the Engine at MIT, uses new technology to create regenerative tissues out of pluripotent stem cells. In other words, they’re creating lab-grown tissues and organs that can one day restore vision loss and treat other diseases.